$8.48
0.28[3.41%]
At close: Apr 25
$8.48
0[0.00%]
After Hours: 5:59PM EDT
Outlook Therapeutics
(NASDAQ:OTLK)Outlook Therapeutics Stock (NASDAQ:OTLK), Analyst Ratings, Price Targets, Predictions
Outlook Therapeutics Inc has a consensus price target of $10.51, established from looking at the 25 latest analyst ratings. The last 3 analyst ratings were released from BTIG, HC Wainwright & Co., and Chardan Capital on March 27, 2024, March 25, 2024, and February 15, 2024. With an average price target of $27.67 between BTIG, HC Wainwright & Co., and Chardan Capital, there's an implied 226.26% upside for Outlook Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BTIG
HC Wainwright & Co.
Chardan Capital
Guggenheim
Brookline Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Outlook Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/27/2024 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | 489.62% | BTIG | Julian Harrison | → $50 | Upgrade | Neutral → Buy | Get Alert |
| 03/25/2024 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | 253.77% | HC Wainwright & Co. | Douglas Tsao | $1.5 → $30 | Maintains | Buy | Get Alert |
| 02/15/2024 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -64.62% | Chardan Capital | Daniil Gataulin | → $60 | Upgrade | Neutral → Buy | Get Alert |
| 01/25/2024 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -76.42% | Guggenheim | Eddie Hickman | → $40 | Upgrade | Neutral → Buy | Get Alert |
| 01/25/2024 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -81.49% | Brookline Capital | Kemp Dolliver | → $31.4 | Upgrade | Hold → Buy | Get Alert |
| 12/29/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -76.42% | Ascendiant Capital | Edward Woo | $30 → $40 | Maintains | Buy | Get Alert |
| 12/27/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -41.04% | Capital One | Zegbeh Jallah | → $100 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/03/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -76.42% | HC Wainwright & Co. | Douglas Tsao | $20 → $40 | Maintains | Buy | Get Alert |
| 08/31/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | — | Chardan Capital | Daniil Gataulin | — | Downgrade | Buy → Neutral | Get Alert |
| 08/31/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -88.21% | HC Wainwright & Co. | Douglas Tsao | → $20 | Downgrade | Buy → Neutral | Get Alert |
| 08/30/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | — | Brookline Capital | Kumaraguru Raja | — | Downgrade | Buy → Hold | Get Alert |
| 08/30/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -88.21% | Cantor Fitzgerald | Kristen Kluska | $90 → $20 | Downgrade | Overweight → Neutral | Get Alert |
| 08/30/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | — | BTIG | Julian Harrison | — | Downgrade | Buy → Neutral | Get Alert |
| 08/15/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -41.04% | HC Wainwright & Co. | Douglas Tsao | → $100 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | 17.92% | Chardan Capital | Daniil Gataulin | → $200 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -41.04% | HC Wainwright & Co. | Douglas Tsao | → $100 | Reiterates | Buy → Buy | Get Alert |
| 07/13/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -41.04% | Capital One | Zegbeh Jallah | → $100 | Initiates | → Overweight | Get Alert |
| 05/16/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | 17.92% | Chardan Capital | Daniil Gataulin | → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | OTLK | Buy Now | Outlook Therapeutics | $8.48 | -41.04% | HC Wainwright & Co. | Douglas Tsao | → $100 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Outlook Therapeutics (OTLK)?
The latest price target for Outlook Therapeutics (NASDAQ: OTLK) was reported by BTIG on March 27, 2024. The analyst firm set a price target for $50.00 expecting OTLK to rise to within 12 months (a possible 489.62% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Outlook Therapeutics (OTLK)?
The latest analyst rating for Outlook Therapeutics (NASDAQ: OTLK) was provided by BTIG, and Outlook Therapeutics upgraded their buy rating.
When was the last upgrade for Outlook Therapeutics (OTLK)?
The last upgrade for Outlook Therapeutics Inc happened on March 27, 2024 when BTIG raised their price target to $50. BTIG previously had a neutral for Outlook Therapeutics Inc.
When was the last downgrade for Outlook Therapeutics (OTLK)?
The last downgrade for Outlook Therapeutics Inc happened on August 31, 2023 when Chardan Capital changed their price target from N/A to N/A for Outlook Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Outlook Therapeutics (OTLK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Outlook Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Outlook Therapeutics was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
Is the Analyst Rating Outlook Therapeutics (OTLK) correct?
While ratings are subjective and will change, the latest Outlook Therapeutics (OTLK) rating was a upgraded with a price target of $0.00 to $50.00. The current price Outlook Therapeutics (OTLK) is trading at is $8.48, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.